SG11202001445XA - Engineered dnase enzymes and use in therapy - Google Patents
Engineered dnase enzymes and use in therapyInfo
- Publication number
- SG11202001445XA SG11202001445XA SG11202001445XA SG11202001445XA SG11202001445XA SG 11202001445X A SG11202001445X A SG 11202001445XA SG 11202001445X A SG11202001445X A SG 11202001445XA SG 11202001445X A SG11202001445X A SG 11202001445XA SG 11202001445X A SG11202001445X A SG 11202001445XA
- Authority
- SG
- Singapore
- Prior art keywords
- therapy
- dnase enzymes
- engineered
- engineered dnase
- enzymes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762547220P | 2017-08-18 | 2017-08-18 | |
| US201762611166P | 2017-12-28 | 2017-12-28 | |
| PCT/US2018/047084 WO2019036719A2 (en) | 2017-08-18 | 2018-08-20 | Engineered dnase enzymes and use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001445XA true SG11202001445XA (en) | 2020-03-30 |
Family
ID=65362608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001445XA SG11202001445XA (en) | 2017-08-18 | 2018-08-20 | Engineered dnase enzymes and use in therapy |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US10696956B2 (en) |
| EP (1) | EP3668972A4 (en) |
| JP (1) | JP2020534865A (en) |
| KR (1) | KR20200047588A (en) |
| CN (1) | CN111566207A (en) |
| AU (1) | AU2018318313A1 (en) |
| BR (1) | BR112020003403A2 (en) |
| CA (1) | CA3073317A1 (en) |
| IL (1) | IL272715A (en) |
| MX (1) | MX2020001913A (en) |
| SG (1) | SG11202001445XA (en) |
| WO (1) | WO2019036719A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11246905B2 (en) | 2016-08-15 | 2022-02-15 | President And Fellows Of Harvard College | Treating infections using IdsD from Proteus mirabilis |
| EP3351263A1 (en) * | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| CA3073317A1 (en) | 2017-08-18 | 2019-02-21 | Neutrolis Therapeutics, Inc. | Engineered dnase enzymes and use in therapy |
| JP2021510539A (en) | 2018-01-16 | 2021-04-30 | シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | Treatment of diseases by liver expression of enzymes with deoxyribonuclease (DNase) activity |
| SG11202103426XA (en) | 2018-10-08 | 2021-05-28 | Neutrolis Inc | Engineering of dnase enzymes for manufacturing and therapy |
| US11058724B2 (en) | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
| US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
| WO2020163264A1 (en) * | 2019-02-04 | 2020-08-13 | Neutrolis, Inc. | Engineered human extracellular dnase enzymes for drug candidate selection |
| US20220251146A1 (en) * | 2019-05-06 | 2022-08-11 | President And Fellows Of Harvard College | Dna-degrading proteins and uses thereof |
| EP4041880A4 (en) * | 2019-10-07 | 2023-08-30 | Texas Tech University System | Mutant dnase1l3 with improved serum half-life |
| AU2021205976A1 (en) * | 2020-01-11 | 2022-07-07 | Yale University | Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with DNAse1 and/or DNAse1L3 deficiency |
| US20230072226A1 (en) * | 2020-02-20 | 2023-03-09 | Neutrolis, Inc. | Basic domain-deleted dnase1-like 3 and uses thereof |
| EP4135739A4 (en) * | 2020-04-15 | 2024-05-15 | Cartesian Therapeutics, Inc. | Engineered cells secreting therapeutic enzymes |
| AU2021288567A1 (en) * | 2020-06-08 | 2023-02-09 | Yale University | Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections |
| US20230416707A1 (en) | 2020-10-07 | 2023-12-28 | Protalix Ltd. | Long-acting dnase |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| US6482626B2 (en) | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US6656685B2 (en) | 2001-01-29 | 2003-12-02 | Ventana Medical Systems, Inc. | Hybridization buffers using low molecular weight dextran sulfate and methods for their use |
| EP1463751B1 (en) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20040138156A1 (en) | 2002-02-26 | 2004-07-15 | Schneider Michael C | Therapeutic regulation of deoxyribonuclease-1-like-3 activity |
| RU2269356C2 (en) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Method for treating oncological patients |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| US8710012B2 (en) | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| US8916151B2 (en) | 2005-04-25 | 2014-12-23 | Cls Therapeutics Limited | Method for treating a reduction of fertility |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| CN101563134A (en) | 2006-10-18 | 2009-10-21 | 派利尼斯有限公司 | Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
| US20090305345A1 (en) | 2006-10-23 | 2009-12-10 | Medical Research Council | Polymerase |
| JP2010530895A (en) * | 2007-06-21 | 2010-09-16 | アンジェリカ セラピューティックス，インク． | Modified toxin |
| LT3460056T (en) * | 2009-11-02 | 2020-12-28 | University Of Washington | Therapeutic nuclease compositions and methods |
| WO2011131772A1 (en) | 2010-04-22 | 2011-10-27 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| JP6143297B2 (en) | 2010-06-04 | 2017-06-07 | チウムバイオ・カンパニー・リミテッドＴｉｕｍＢｉｏ Ｃｏ．， Ｌｔｄ． | Fusion protein having factor VII activity |
| US9198957B2 (en) | 2011-01-31 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Treatment and prevention of bacterial vaginosis and Gardnerella vaginalis infections |
| US9642822B2 (en) | 2011-05-27 | 2017-05-09 | Children's Medical Center Corporation | Methods for treating and preventing neutrophil-derived net toxicity and thrombosis |
| BR112014014378A2 (en) | 2011-12-12 | 2020-05-19 | Univ Illinois | composition and use to treat eye disease related to nucleic acid |
| GB201208879D0 (en) | 2012-05-21 | 2012-07-04 | London School Hygiene & Tropical Medicine | Therapeutic for treating Clostridium difficile infection |
| DK3063275T3 (en) | 2013-10-31 | 2019-11-25 | Resolve Therapeutics Llc | THERAPEUTIC NUCLEASE ALBUMIN MERGERS AND PROCEDURES |
| WO2015130416A1 (en) * | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| KR20170045750A (en) | 2014-09-08 | 2017-04-27 | 고담 바이오파마슈티컬스 인크. | Methods of Treating Pulmonary Sarcoidosis |
| EP3247386A4 (en) | 2015-01-20 | 2018-10-03 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
| CN107533058A (en) | 2015-03-01 | 2018-01-02 | 免疫阵列有限公司 | Use albumen, peptide and oligonucleotides diagnostic antigen systemic loupus erythematosus |
| EP3273238A1 (en) | 2016-07-22 | 2018-01-24 | Universitätsklinikum Hamburg-Eppendorf | Immunodiagnostic detection of anti-neutrophil antibodies |
| CA3105873A1 (en) | 2016-09-30 | 2018-04-05 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| EP3570667B1 (en) | 2017-01-20 | 2022-11-16 | Neutrolis Inc. | Animal model for drug development |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| CA3073317A1 (en) | 2017-08-18 | 2019-02-21 | Neutrolis Therapeutics, Inc. | Engineered dnase enzymes and use in therapy |
-
2018
- 2018-08-20 CA CA3073317A patent/CA3073317A1/en active Pending
- 2018-08-20 MX MX2020001913A patent/MX2020001913A/en unknown
- 2018-08-20 EP EP18846060.4A patent/EP3668972A4/en active Pending
- 2018-08-20 KR KR1020207007703A patent/KR20200047588A/en not_active Application Discontinuation
- 2018-08-20 WO PCT/US2018/047084 patent/WO2019036719A2/en unknown
- 2018-08-20 CN CN201880068103.8A patent/CN111566207A/en active Pending
- 2018-08-20 SG SG11202001445XA patent/SG11202001445XA/en unknown
- 2018-08-20 BR BR112020003403-7A patent/BR112020003403A2/en unknown
- 2018-08-20 JP JP2020531567A patent/JP2020534865A/en active Pending
- 2018-08-20 AU AU2018318313A patent/AU2018318313A1/en active Pending
-
2019
- 2019-08-02 US US16/530,141 patent/US10696956B2/en active Active
-
2020
- 2020-02-17 IL IL272715A patent/IL272715A/en unknown
- 2020-07-15 US US16/929,980 patent/US10801019B1/en active Active
- 2020-09-11 US US17/018,642 patent/US11046942B2/en active Active
- 2020-10-12 US US17/068,105 patent/US11046943B2/en active Active
-
2021
- 2021-03-05 US US17/193,455 patent/US20210277372A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210040461A1 (en) | 2021-02-11 |
| EP3668972A4 (en) | 2021-04-21 |
| US10696956B2 (en) | 2020-06-30 |
| US11046943B2 (en) | 2021-06-29 |
| US20200024585A1 (en) | 2020-01-23 |
| CA3073317A1 (en) | 2019-02-21 |
| WO2019036719A2 (en) | 2019-02-21 |
| AU2018318313A1 (en) | 2020-03-19 |
| WO2019036719A3 (en) | 2019-03-28 |
| IL272715A (en) | 2020-04-30 |
| US20200347370A1 (en) | 2020-11-05 |
| BR112020003403A2 (en) | 2020-08-25 |
| CN111566207A (en) | 2020-08-21 |
| MX2020001913A (en) | 2020-09-07 |
| US11046942B2 (en) | 2021-06-29 |
| US10801019B1 (en) | 2020-10-13 |
| JP2020534865A (en) | 2020-12-03 |
| US20210277372A1 (en) | 2021-09-09 |
| US20200399622A1 (en) | 2020-12-24 |
| EP3668972A2 (en) | 2020-06-24 |
| KR20200047588A (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272715A (en) | Engineered dnase enzymes and use in therapy | |
| HK1245287A1 (en) | IL13RAα2 BINDING AGENTS AND USE THEREOF IN CANCER TREATMENT | |
| IL281171A (en) | Cellulose-synthase-like enzymes and uses thereof | |
| ZA201904966B (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| IL282836A (en) | 5-halouracil-modified micrornas and their use in the treatment of cancer | |
| GB201604213D0 (en) | Drug combination and its use in therapy | |
| ZA201904967B (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| DK3681857T3 (en) | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | |
| GB201514021D0 (en) | Novel Pyridines and their use in the treatment of cancer | |
| EP3236992A4 (en) | Peptides and their use in the treatment of skin | |
| HK1251013A1 (en) | Histamine-producing bacterial strains and their use in cancer | |
| GB201507722D0 (en) | Anti-bacterial agents and their use in therapy | |
| GB201820659D0 (en) | Novel compostions and their use in therapy | |
| GB201507723D0 (en) | Anti-bacterial agents and their use in therapy | |
| GB201709840D0 (en) | Methods and medical uses | |
| SG11202004529XA (en) | Transformed human cell and use thereof | |
| GB201507721D0 (en) | Immunosuppressive agents and their use in therapy | |
| GB201514015D0 (en) | Novel pyridazinones and their use in the treatment of cancer | |
| EP3665281A4 (en) | CONDITIONAL-siRNAS AND USES THEREOF IN TREATING CARDIAC HYPERTROPHY | |
| IL280555A (en) | Substituted benzamides and their use in therapy | |
| IL269817A (en) | Macro-encapsulated therapeutic cells and methods of using the same | |
| SG11202000509PA (en) | Nanostructured and biocompatible biocatalysts for use in cancer treatment | |
| EP3544622A4 (en) | Peptidomimetics and their use in therapy | |
| GB201916497D0 (en) | Improvements in or relating to devices and methods | |
| IL271555A (en) | Combination and uses and treatments thereof |